Post by JHam on Aug 6, 2014 10:21:09 GMT
Really nice news. ONCS continues to compile a world class scientific team to oversee trials:
ir.oncosec.com/company-news/detail/1494
OncoSec Medical Appoints Dr. Holbrook Kohrt to Scientific Advisory Board
SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, has appointed Dr. Holbrook Kohrt, M.D., Ph.D., to the company’s Scientific Advisory Board. Dr. Kohrt joins a growing panel of distinguished experts and renowned thought leaders, and will contribute his considerable expertise to the company as it works to advance an expanding immuno-oncology pipeline.
Holbrook E. Kohrt, M.D., Ph.D., is an Assistant Professor at Stanford Cancer Institute, and currently investigates novel therapeutic strategies to enhance anti-tumor immunity. Dr. Kohrt attended Stanford University Medical School as the Baxter Foundation Scholar, Howard Hughes Scholar, and American Society of Hematology Research Fellow. During this time he developed, validated, and nationally implemented a nomogram for risk prediction in early stage breast cancer.
Dr. Kohrt trained in Internal Medicine at Stanford University through the Clinical Investigator Pathway and completed fellowship in Hematology and Oncology at Stanford with a research focus on preclinical models of novel immunomodulatory antibodies. He received his Ph.D. in clinical trial design and tumor immunology from Stanford. Most notably, Dr. Kohrt along with Dr. Ron Levy at Stanford have been the academic leaders in the advancement of intratumoral immuno-oncology therapies. Recently, they conducted a Phase I/II clinical trial using CG-enriched oligodeoxynucleotide (CpG), a ligand for the Toll-like receptor 9 (TLR9) in non-Hodgkin’s lymphoma. As well, they have demonstrated that intratumoral administration of the checkpoint inhibitor, anti-CTLA-4 antibody, is a safe and effective route of therapy in mice, demonstrating both local and systemic responses.
“We are extremely excited to have Dr. Kohrt join our scientific advisory board”, said Punit Dhillon, President and CEO. “Holbrook’s background and experience will be invaluable as we not only move our ImmunoPulse program forward into later stage clinical development, but he and the rest of the SAB, will also be integral in keeping our intratumoral immunotherapy platform at the cutting edge of scientific advances.”
Dr. Kohrt said, “OncoSec’s DNA-based intratumoral immunotherapy technology has the potential to address an important unmet medical need in cancer immunotherapy. I am pleased to help guide OncoSec’s scientific team as it continues to target difficult diseases and advance new intratumoral therapeutic targets for the treatment of cancer.”
ir.oncosec.com/company-news/detail/1494
OncoSec Medical Appoints Dr. Holbrook Kohrt to Scientific Advisory Board
SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, has appointed Dr. Holbrook Kohrt, M.D., Ph.D., to the company’s Scientific Advisory Board. Dr. Kohrt joins a growing panel of distinguished experts and renowned thought leaders, and will contribute his considerable expertise to the company as it works to advance an expanding immuno-oncology pipeline.
Holbrook E. Kohrt, M.D., Ph.D., is an Assistant Professor at Stanford Cancer Institute, and currently investigates novel therapeutic strategies to enhance anti-tumor immunity. Dr. Kohrt attended Stanford University Medical School as the Baxter Foundation Scholar, Howard Hughes Scholar, and American Society of Hematology Research Fellow. During this time he developed, validated, and nationally implemented a nomogram for risk prediction in early stage breast cancer.
Dr. Kohrt trained in Internal Medicine at Stanford University through the Clinical Investigator Pathway and completed fellowship in Hematology and Oncology at Stanford with a research focus on preclinical models of novel immunomodulatory antibodies. He received his Ph.D. in clinical trial design and tumor immunology from Stanford. Most notably, Dr. Kohrt along with Dr. Ron Levy at Stanford have been the academic leaders in the advancement of intratumoral immuno-oncology therapies. Recently, they conducted a Phase I/II clinical trial using CG-enriched oligodeoxynucleotide (CpG), a ligand for the Toll-like receptor 9 (TLR9) in non-Hodgkin’s lymphoma. As well, they have demonstrated that intratumoral administration of the checkpoint inhibitor, anti-CTLA-4 antibody, is a safe and effective route of therapy in mice, demonstrating both local and systemic responses.
“We are extremely excited to have Dr. Kohrt join our scientific advisory board”, said Punit Dhillon, President and CEO. “Holbrook’s background and experience will be invaluable as we not only move our ImmunoPulse program forward into later stage clinical development, but he and the rest of the SAB, will also be integral in keeping our intratumoral immunotherapy platform at the cutting edge of scientific advances.”
Dr. Kohrt said, “OncoSec’s DNA-based intratumoral immunotherapy technology has the potential to address an important unmet medical need in cancer immunotherapy. I am pleased to help guide OncoSec’s scientific team as it continues to target difficult diseases and advance new intratumoral therapeutic targets for the treatment of cancer.”